SoFi CEO enters prepaid forward contract on 1.5 million shares
Investing.com -- Halozyme Therapeutics Inc (NASDAQ:HALO) shares surged 5.3% after the company reported second-quarter earnings that significantly exceeded analyst expectations and raised its full-year guidance for the second time this year.
The biopharmaceutical company posted adjusted earnings per share of $1.54 for the quarter ended June 30, 2025, handily beating the analyst consensus of $1.24. While reported revenue came in at $326 million compared to analyst estimates of $286.01 million, the company highlighted that royalty revenue jumped 65% YoY to $205.6 million, driven by strong performance from its three blockbuster therapies: DARZALEX SC, Phesgo, and VYVGART Hytrulo.
"We are very excited to report another quarter of exceptional growth with a 65% increase in royalty revenue driven by our current three blockbuster therapies," said Dr. Helen Torley, President and CEO of Halozyme.
The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 billion, topping analyst expectations of $1.25 billion.
The strong performance was bolstered by several regulatory approvals during the quarter, including RYBREVANT SC in Europe and new indications for VYVGART Hytrulo. The company also completed $303 million in share repurchases during the quarter.
"The strong results highlight the momentum and durability across our business, powered by high-margin royalty streams and increasing global demand for our industry-leading ENHANZE drug delivery technology," added Dr. Torley.
Operating income for the quarter reached $202.4 million, up from $117.2 million in the same period last year, while adjusted EBITDA rose to $225.5 million from $137.0 million in Q2 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.